Posted inHematology-Oncology news Oncology
Evaluating Myeloablative Treosulfan-Fludarabine Conditioning in AML: A Promising Alternative for Middle-Aged Adults
A phase II trial demonstrates the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning in AML patients aged 40-65, showing high leukemia-free survival and low toxicity, supporting its use over busulfan regimens in selected cases.



















